CD274 and head and neck squamous cell carcinoma: These findings together with high MHC-I (~95%) and notable MHC-II (~70%) expression align with published literature showing that HNSCC can retain robust antigen-presentation capacity while simultaneously upregulating inhibitory ligands such as PD-L1 to evade cytotoxic T cell responses (17).